Provided by Tiger Trade Technology Pte. Ltd.

HANSOH PHARMA

34.500
-0.840-2.38%
Volume:3.81M
Turnover:132.72M
Market Cap:209.21B
PE:31.80
High:35.680
Open:35.680
Low:34.380
Close:35.340
52wk High:43.939
52wk Low:27.882
Shares:6.06B
HK Float Shares:6.06B
Volume Ratio:1.12
T/O Rate:0.06%
Dividend:0.49
Dividend Rate:1.43%
EPS(LYR):1.085
ROE:19.40%
ROA:9.08%
PB:4.75
PE(LYR):31.80
PS:11.28

Loading ...

HANSOH PHARMA's B7-H3-Targeting ADC HS-20093 Designated as Breakthrough Therapy for Esophageal Squamous Cell Carcinoma

Stock News
·
May 11

Hansoh says China NMPA grants breakthrough therapy status for HS-20093 in esophageal cancer

Reuters
·
May 11

Hansoh Pharmaceutical - Nmpa Grants Breakthrough-Therapy Designation to Hansoh Pharma's Hs-20093 for Escc

THOMSON REUTERS
·
May 11

Hansoh Pharmaceutical Group Stock Slips 3.8% in Hong Kong

Dow Jones
·
May 08

AI Frenzy Shifts from Hardware to Applications, Musk-Related Concepts Gain Traction

Stock News
·
May 07

Hansoh Pharmaceutical Group SEHK 3692 Valuation After New Breakthrough Therapy And Hypertension Trial Approvals

Simply Wall St.
·
May 05

Hansoh Pharmaceutical Group Stock Slips 1.4% in Hong Kong

Dow Jones
·
May 05

Hansoh Pharma Issues 9.00 Million New Shares Under RSU Scheme, Expanding Outstanding Share Base to 6.06 Billion

Bulletin Express
·
May 04

HANSOH PHARMA buys 370,000 shares for RSU scheme at HK$39.11 each, spending HK$14.47 million

Bulletin Express
·
Apr 30

Hansoh RSU trustee buys 370,000 shares for HK$14.47 million in market purchases

Reuters
·
Apr 30

HANSOH PHARMA Trustee Purchases 370,000 Shares Under Restricted Share Unit Plan

Stock News
·
Apr 30

Hansoh Pharma Secures Dual NMPA Clinical Trial Approvals for HS-10522 Targeting Hypertension and Primary Aldosteronism

Bulletin Express
·
Apr 29

Hansoh Pharma Secures NMPA Breakthrough-Therapy Designation for B7-H3 ADC HS-20093 in Metastatic Castration-Resistant Prostate Cancer

Bulletin Express
·
Apr 29

HANSOH PHARMA's B7-H3-Targeting ADC Candidate HS-20093 Granted Breakthrough Therapy Designation for Prostate Cancer

Stock News
·
Apr 29

Hansoh says China NMPA grants breakthrough designation for HS-20093 in prostate cancer

Reuters
·
Apr 29

Hansoh Pharmaceutical - Nmpa Grants Breakthrough-Therapy Designation to Hansoh's Hs-20093 for Prostate Cancer

THOMSON REUTERS
·
Apr 29

Hansoh Pharmaceutical - Clinical Trial Approvals for Hs-10522 Tablets Issued by Nmpa

THOMSON REUTERS
·
Apr 29

Hansoh Pharmaceutical - Clinical Trial Approvals for Hs-10522 Tablets- Issued by National Medical Products Administration

THOMSON REUTERS
·
Apr 29

Hansoh Pharma wins China NMPA clinical trial approvals for HS-10522 tablets

Reuters
·
Apr 29

Hansoh Pharma transfers KiOmedinevsOne China license to Hengrui for RMB 131 million

Reuters
·
Apr 29